Neural Regeneration Research ›› 2025, Vol. 20 ›› Issue (4): 1094-1095.doi: 10.4103/NRR.NRR-D-24-00187

Previous Articles     Next Articles

Brain-penetrating neurotrophic factor mimetics: HER-096 as a disease-modifying therapy for Parkinson’s disease

Natalia Kulesskaya, Kira M. Holmström, Henri J. Huttunen*   

  1. Herantis Pharma Plc, Espoo, Finland
  • Online:2025-04-15 Published:2024-07-01
  • Contact: Henri J. Huttunen, PhD, henri.huttunen@herantis.com.
  • Supported by:
    This work has been supported by Herantis Pharma Plc and the European Innovation Council (grant acronym ReTreatPD).

Abstract: Neurotrophic factors as a therapeutic approach in neurodegenerative diseases: A major unmet need in the field of central nervous system diseases is disease-modifying treatments. While for decades there have been various symptomatic treatments available to alleviate the symptoms of the disease, disease-modification, i.e. treatments that stop, significantly delay, or reverse the progression of the disease, has been turned out to a difficult goal to achieve.